Skip to main content

Table 1 Demographic and clinical characteristics, overall and by country

From: A multicenter chart review of patient characteristics, treatment, and outcomes in hereditary angioedema: unmet need for more effective long-term prophylaxis

 

Overall (N = 225)

US (n = 56)

Canada (n = 51)

Germany (n = 45)

Australia (n = 35)

UK (n = 24)

Italy (n = 14)

Follow-up duration (y), mean ± SD

5.5 ± 4.2

5.2 ± 4.0

7.0 ± 4.2

5.6 ± 3.4

5.9 ± 5.9

5.0 ± 2.3

1.3 ± 1.2

Year of index date, n (%)a

 2008 or earlier

37 (16.4)

5 (8.9)

17 (33.3)

9 (20.0)

6 (17.1)

0

0

 2009–2011

52 (23.1)

20 (35.7)

9 (17.6)

8 (17.8)

8 (22.9)

7 (29.2)

0

 2012–2014

56 (24.9)

8 (14.3)

19 (37.3)

13 (28.9)

7 (20.0)

6 (25.0)

3 (21.4)

 2015–2017

69 (30.7)

18 (32.1)

6 (11.8)

13 (28.9)

12 (34.3)

10 (41.7)

10 (71.4)

 2018 or later

11 (4.9)

5 (8.9)

0

2 (4.4)

2 (5.7)

1 (4.2)

1 (7.1)

Age at index date, mean ± SDa

36.8 ± 15.6

34.0 ± 12.9

35.7 ± 16.6

42.3 ± 15.8

32.1 ± 14.0

41.7 ± 17.6

38.0 ± 16.0

Female sex, n (%)

141 (62.7)

39 (69.6)

35 (68.6)

27 (60.0)

18 (51.4)

16 (66.7)

6 (42.9)

Race/ethnicity, n (%)

 White

194 (86.2)

52 (92.9)

51 (100.0)

27 (60.0)

32 (91.4)

22 (91.7)

10 (71.4)

 Otherb

7 (3.1)

4 (7.1)

0

0

3 (8.6)

0

0

 Unknown

24 (10.7)

0

0

18 (40.0)

0

2 (8.3)

4 (28.6)

Type of HAE, n (%)

 Type 1

203 (90.2)

46 (82.1)

49 (96.1)

40 (88.9)

31 (88.6)

23 (95.8)

14 (100.0)

 Type 2

22 (9.8)

10 (17.9)

2 (3.9)

5 (11.1)

4 (11.4)

1 (4.2)

0

Family history of HAE, n (%)

 Yes

160 (71.1)

46 (82.1)

33 (64.7)

27 (60.0)

24 (68.6)

20 (83.3)

10 (71.4)

 No

38 (16.9)

8 (14.3)

13 (25.5)

8 (17.8)

2 (5.7)

3 (12.5)

4 (28.6)

 Unknown

27 (12.0)

2 (3.6)

5 (9.8)

10 (22.2)

9 (25.7)

1 (4.2)

0

Comorbidities, (%)c

 Any comorbidities

105 (46.7)

29 (51.8)

34 (66.7)

12 (26.7)

17 (48.6)

9 (37.5)

4 (28.6)

  Allergy or anaphylaxisd

36 (16.0)

8 (14.3)

18 (35.3)

2 (4.4)

7 (20.0)

0

1 (7.1)

  Metabolice

25 (11.1)

10 (17.9)

6 (11.8)

3 (6.7)

4 (11.4)

2 (8.3)

0

  Psychiatricf

25 (11.1)

9 (16.1)

8 (15.7)

1 (2.2)

6 (17.1)

1 (4.2)

0

  Cardiovascularg

22 (9.8)

5 (8.9)

5 (9.8)

4 (8.9)

4 (11.4)

3 (12.5)

1 (7.1)

  Gastrointestinalh

20 (8.9)

2 (3.6)

13 (25.5)

0

3 (8.6)

1 (4.2)

1 (7.1)

  Canceri

9 (4.0)

0

6 (11.8)

1 (2.2)

1 (2.9)

1 (4.2)

0

  Autoimmunej

3 (1.3)

0

1 (2.0)

2 (4.4)

0

0

0

  1. HAE hereditary angioedema
  2. aThe index date is defined as the patient’s first HAE-related visit at the clinical center
  3. bOther includes Asian, Black, Hispanic, and other
  4. cComorbidities occurring in > 5% overall are listed; malignancies and autoimmune disorders have a frequency < 5% but are also listed owing to particular interest in HAE and decreased complement levels
  5. dAllergy or anaphylaxis included allergy, anaphylaxis, and allergic rhinitis
  6. eMetabolic included obesity, diabetes, hypercalcemia, hyperthyroidism, dyslipidemia, hyperlipidemia, and hypothyroidism
  7. fPsychiatric disorders included anxiety or depression, posttraumatic stress disorder, psychosis, attention deficit hyperactivity disorder, bipolar disorder, chronic schizophrenia, and disassociation personality disorder
  8. gCardiovascular included hypertension, cerebrovascular disease, hypercholesterolemia, myocardial infarction, congestive heart failure, peripheral vascular disease, pulmonary emboli, and cardiac arrhythmia
  9. hGastrointestinal included gastroesophageal reflux disease, hemorrhoid, irritable bowel syndrome, Schatzki’s ring, Crohn’s disease, diverticular disease, diverticulitis, peptic ulcer disease, ulcerative colitis, diverticulosis, inflammatory bowel syndrome, and gastric ulcer
  10. iCancer included prostate cancer, lymphoma, chronic lymphocytic leukemia, and adrenal myelolipoma
  11. jAutoimmune included Graves’ disease, autoimmune thyroiditis, and immune defect
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us